MedTrace Logo

Adipose Stem Cell Mitochondria Supplementation to Oocytes (ASCENT)

NCT07066267 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2025-07-17

No results posted yet for this study

Summary

The purpose of this study is to investigate the potential of autologous adipose stem cell (ASC) mitochondrial transfer (ASCENT) to oocytes along with intracytoplasmic sperm injection (ICSI)as a means of enhancing embryo development and improving the success rate of in patients with a history of multiple IVF failures. Embryo quality plays a crucial role in determining the success of assisted reproductive technologies and directly contributes to repeated pregnancy failures. Several factors, including age, physiological conditions, genetics, and environmental influences, can significantly impact embryo quality. Oocytes, the largest cells in the human body, are heavily reliant on mitochondria. Mitochondria's role in providing energy for oocytes is crucial, and insufficient energy production has been linked to poor oocyte and embryo quality. Some human studies have shown that increasing oocyte mitochondrial mass can improve embryo quality in patients who have experienced repeated IVF failures.

Conditions

  • Female Infertility
  • Oocyte Competence
  • Mitochondria
  • Recurent Implantation Failures
  • Advanced Age

Interventions

OTHER

Experimental

Autologous adipose stem cell mitochondrial transfer to mature oocytes along with intracytoplasmic sperm injection (ICSI). The intervention is also termed as Adipose Stem Cell ENergy Transfer (ASCENT).

Sponsors & Collaborators

  • Wish Fertility Hospital Pvt. Ltd

    collaborator UNKNOWN

  • Sunkaky Medical Cooperation

    lead INDUSTRY

Principal Investigators

  • Dr. Helaruwan Pasan Kumara WA, MD, PhD · Wish Fertility Hospital Pvt. Ltd

  • Prof. Yoshiharu Morimoto, MD, PhD · Horac Grand Front Osaka Clinic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
29 Years
Max Age
39 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-25
Primary Completion
2025-12-31
Completion
2026-12-31

Countries

  • Sri Lanka

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07066267 on ClinicalTrials.gov